Patrys is a Melbourne based publicly-listed company on the Australian Securities Exchange (ASX:PAB). Our principal focus is on the development of a new type of products for the treatment of cancer.
These natural human antibodies potentially offer the promise of increased potency coupled with greater safety as compared to existing cancer treatments.
The Company’s most mature product is PAT-SC1, has been shown to provide treated gastric cancer patients with a 10 year survival benefit. Patrys has signed an exclusive development and commercialisation deal for all oncology indications in China for PAT-SC1. Patrys retains the right to develop and commercialise PAT-SC1 outside of China.
Patrys has also successfully advanced a second product into the clinic: in July of 2010 Patrys received regulatory approval to evaluate PAT-SM6 in a first-in-human clinical trial for the treatment of melanoma patients. This trial was completed in February 2012 with promising results, including a complete absence of adverse events and localisation of PAT-SM6 to tumour cells.
In March 2014 Patrys completed a Phase I/IIa clinical trial in multiple myeloma for PAT-SM6. The primary endpoint of the study was safety and tolerability. At all dose levels PAT-SM6 was well tolerated with no serious adverse events of dose limiting toxicities. Overall, 4/12 patients (33%) treated with PAT-SM6 showed evidence of stable disease according to the International Myeloma Working Group (IMWG) criteria. The next clinical trial for PAT-SM6 is currently on hold.
In addition to PAT-SC1 and PAT-SM6, Patrys has a deep pipeline of other promising products, which Patrys can use to refill its pipeline. These include PAT-LM1, which has a strong preclinical profile, and which Patrys is looking to move to the clinical setting.
In March 2016, Patrys licensed the exclusive rights to two nuclear-penetrating lupus antibodies for cancer therapy from Yale University. The most advanced program Deoxymab (3E10) is a novel cancer therapy that has the capacity to penetrate cancer cell nuclei, inhibit DNA repair and kill DNA repair-deficient cancer cells with BRACA2 and PTEN. The antibody has the ability to sensitise cancer cells to radiation and chemotherapy and interfere with their ability to sustain themselves through DNA repair. These characteristics of Deoxymab open up new avenues for researching treatment of BRCA2 and PTEN-related cancers including breast, brain gliomas, astrocytomas, head and neck carcinoma as examples.
Deoxymab has been re-formatted as a Di-single chain fragment (scFv), without the Fc region of a typical IgG which is likely to reduce the risk of non-specific activation. Patrys has initiated a preclinical development plan. Patrys has also licensed the rights from Yale University to second antibody 5C6, which also has cell penetrating characteristics. This antibody will be positioned in the back-up antibody program.
Patrys’ IgM patent portfolio includes multiple patent families. The portfolio covers all lead products, and patents have already been issued in all major markets including the United States, Europe, Japan, Canada, and Australia. These filings cover our novel antibodies, newly discovered disease targets, and production technologies.
Deoxymab and 5C6 antibodies are covered by 3 patents with filings in United States, Europe and other jurisdications.